Reported about 5 hours ago
Novo Nordisk has escalated its bid for the development-stage drugmaker Metsera to $10 billion, outbidding Pfizer's previous offer and triggering a negotiation period. Metsera announced the new offer, which raises the cash payment per share and includes contingent value rights. In response, Pfizer has altered its proposal but expressed doubts about the feasibility of Novo's offer.
Source: YAHOO